Pyxis Oncology, Inc. (PYXS)
| Market Cap | 277.75M +99.0% |
| Revenue (ttm) | 11.04M +291.4% |
| Net Income | -88.73M |
| EPS | -1.40 |
| Shares Out | 83.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 251,964 |
| Open | 3.210 |
| Previous Close | 3.190 |
| Day's Range | 3.190 - 3.405 |
| 52-Week Range | 1.030 - 5.550 |
| Beta | 1.34 |
| Analysts | Strong Buy |
| Price Target | 8.44 (+153.45%) |
| Est. Earnings | Nov 2, 2026 |
About PYXS
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-o... [Read more]
Financial Performance
In 2025, Pyxis Oncology's revenue was $13.86 million, a decrease of -14.17% compared to the previous year's $16.15 million. Losses were -$79.62 million, 2.96% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for PYXS stock is "Strong Buy." The 12-month stock price target is $8.44, which is an increase of 153.45% from the latest price.
News
Pyxis Oncology price target raised to $8 from $7 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Pyxis Oncology (PYXS) to $8 from $7 and keeps a Buy rating on the shares. The company’s updated data…
Pyxis Oncology price target raised to $19 from $12 at Wells Fargo
Wells Fargo raised the firm’s price target on Pyxis Oncology (PYXS) to $19 from $12 and keeps an Overweight rating on the shares after the company announced updated data as…
Pyxis Oncology announces updated results from micvotabart pelidotin study
Pyxis Oncology (PYXS) announced updated data as of the August 18 data cutoff date from its ongoing global Phase 1 monotherapy study evaluating micvotabart pelidotin in patients with second-line and…
Pyxis Oncology Transcript: Study update
MICVO demonstrated a 36% confirmed response rate and 94% disease control rate in heavily pretreated head and neck cancer patients, with a median PFS of 6.2 months and a 12-month OS probability of 79%. Safety was manageable, and efficacy was consistent across key subgroups.
Pyxis Oncology Press release: Study update
Pyxis Oncology issued a press release on September 9, 2026, disclosing material business information to investors.
Pyxis Oncology Slides: Study update
Pyxis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatme...
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it...
Pyxis Oncology appoints Thomas Civik as CEO, chairman
Pyxis Oncology (PYXS) announced that its board of directors has appointed Thomas Civik as CEO and chairman of the board, effective as of September 4. Civik has served as interim…
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
John Flavin, Co-Founder and Founding Chairman, to serve as Lead Independent Director of the Board Leadership transition reflects continued focus on advancing MICVO through key clinical milestones BOST...
Pyxis Oncology to Participate in Upcoming Investor Conferences
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that To...
Pyxis Oncology files to sell 39.2M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 39.2M shares of common stock. The company is not selling any…
Pyxis Oncology Registration statement: Registration filing
Pyxis Oncology filed a registration statement on August 20, 2026, providing details about a securities offering with the SEC.
Pyxis Oncology reports Q2 EPS (40c), consensus (35c)
“The second quarter was marked by continued execution across the MICVO program and a financing that strengthened our balance sheet and extended our cash runway into the second quarter of…
Pyxis Oncology Slides: Corporate presentation
Pyxis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap Updated data...
Pyxis Oncology Quarterly report: Q2 2026
Pyxis Oncology has published its Q2 2026 quarterly earnings report on August 13, 2026.
Pyxis Oncology Earnings release: Q2 2026
Pyxis Oncology released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Pyxis Oncology initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of Pyxis Oncology (PYXS) with an Overweight rating and $12 price target The firm says dose capping likely addresses concerns on Micvo’s safety. In addition, the…
Pyxis Oncology announces up to $114M private placement
Pyxis Oncology (PYXS) announced that it has entered into definitive securities purchase agreements for a private placement expected to result in gross proceeds of approximately $50M, before deducting ...
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap
Pyxis Oncology Transcript: Jefferies Global Healthcare Conference 2026
A novel ADC targeting the tumor stroma is advancing in head and neck cancer, with mid-year data to clarify efficacy, safety, and regulatory path. Dose capping addresses safety in high body weight patients, and combination strategies are underway.
Pyxis Oncology Transcript: Stifel 2026 Targeted Oncology Virtual Forum
MICVO, an ADC targeting EDB-FN, has shown strong efficacy in head and neck cancer, with a 46–50% response rate at high doses and promising safety improvements via dose capping. Key monotherapy and combination data updates are expected mid-year and in the second half of the year.
Pyxis Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2026
MICVO, a novel ADC, has shown strong efficacy in second-line head and neck cancer, with a 46% response rate and promising safety improvements through dose capping. Ongoing trials and translational research support its potential in combination therapies and broader cancer indications.
Pyxis Oncologyreports Q1 EPS (37c), consensus (35c)
“Our team’s exceptional clinical and operational execution in the first quarter of 2026, combined with growing investigator enthusiasm for MICVO’s potential to positively impact the lives of patients ...